Monitor for the 8-K filing of the audited balance sheet reflecting the receipt of proceeds within four business days after closing. The next catalyst is the identification of a business combination target; the 24-month deadline from October 15, 2026 is October 2028. No immediate price catalyst.
Price Chart
Executive Summary
Frazier Life Sciences Acquisition Corp. II filed an 8-K documenting the execution of an underwriting agreement for its IPO of 7,500,000 Class A ordinary shares at $10.00 per share, the adoption of amended and restated charter documents, and entry into related agreements (registration rights, private placement, forward purchase, trust, and insider letter). The IPO closed on October 15, 2026, with net proceeds deposited into a trust account. The filing is a standard blank-check company IPO — no operational results, no business combination target identified, and no financial data beyond the IPO proceeds.
Key Financial Metrics
Key Facts
- IPO of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75,000,000 in gross proceeds
- Underwriter purchase price: $9.80 per share; deferred discount of $0.40 per share held in trust until business combination
- Sponsor purchased 300,000 private placement shares at $10.00 per share in a concurrent private placement
- Forward purchase agreement with Frazier Life Sciences Public Fund, L.P. for 2,500,000 Class A shares at $10.00 per share, generating $25,000,000 gross proceeds, closing concurrently with initial business combination
- Trust account established with Continental Stock Transfer & Trust Company as trustee
- Founder shares: 1,875,000 Class B ordinary shares outstanding; 281,000 founder shares surrendered in September 2026
- Registration rights agreement grants demand and piggyback registration rights for founder shares, private placement, and working capital shares
- Amended and restated memorandum and articles of association adopted effective October 13, 2026
- No business combination target identified; company has 24 months from IPO closing to complete a business combination or liquidate
- No financial statements, no revenue, no earnings, no guidance, no analyst consensus provided
Financial Impact
IPO gross proceeds of $75,000,000 from 7,500,000 Class A shares at $10.00 per share; $25,000,000 forward purchase commitment from Frazier Life Sciences Public Fund, L.P. at $10.00 per share
Risk Factors
- No identified business combination target identified; no revenue or operations
- Dilution from 7,500,000 IPO shares, 300,000 private placement shares, 2,500,000 forward purchase shares, and up to 300,000 working capital shares (total up to 10,600,000 potential shares beyond founder shares)
- If no business combination within 24 months, liquidation and liquidation distribution to public shareholders
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-422919 |
| Document: d417884dex11.htm | 0001193125-26-422919 |
| Document: d417884dex102.htm | 0001193125-26-422919 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $10.30 | awaiting T+5 | — | $10.28 (−0.19%) |
Oct 22, 2026 4d ago | SC 13G | $10.30 | awaiting T+5 | — | $10.28 (−0.19%) |
Oct 21, 2026 5d ago | SC 13D | $10.27 | awaiting T+5 | — | $10.28 (+0.10%) |
Oct 21, 2026 5d ago | SC 13G | $10.27 | awaiting T+5 | — | $10.28 (+0.10%) |
Oct 21, 2026 5d ago | SC 13G | $10.27 | awaiting T+5 | — | $10.28 (+0.10%) |
Oct 16, 2026 10d ago | SC 13G | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.28 (−0.68%) |
Oct 15, 2026 11d ago | Insider Buy | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.28 (−0.68%) |
Oct 15, 2026 11d ago | 8-K | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.28 (−0.68%) |
Oct 14, 2026 12d ago | 424B4 | $10.49 $10.27 | ▼ −2.10% | ▼ −1.08% | $10.28 (−2.00%) |
Oct 14, 2026 12d ago | EFFECT | $10.29 $10.30 | ▲ +0.10% | ▼ −0.36% | $10.28 (−0.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers